Mesoblast (NASDAQ:MESO) Director Buys $2,285,121.60 in Stock
by Teresa Graham · The Cerbat GemMesoblast Limited (NASDAQ:MESO – Get Free Report) Director Gregory George bought 1,586,890 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were acquired at an average price of $1.44 per share, with a total value of $2,285,121.60. Following the purchase, the director owned 13,586,890 shares of the company’s stock, valued at $19,565,121.60. The trade was a 13.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Gregory George also recently made the following trade(s):
- On Friday, April 10th, Gregory George bought 2,324,072 shares of Mesoblast stock. The shares were acquired at an average price of $1.48 per share, with a total value of $3,439,626.56.
- On Thursday, April 9th, Gregory George bought 1,981,890 shares of Mesoblast stock. The shares were acquired at an average price of $8.59 per share, with a total value of $17,024,435.10.
- On Saturday, April 4th, Gregory George bought 4,000,000 shares of Mesoblast stock. The stock was purchased at an average cost of $1.42 per share, with a total value of $5,680,000.00.
Mesoblast Stock Up 7.8%
Shares of NASDAQ MESO opened at $15.75 on Thursday. The stock has a market cap of $2.03 billion, a PE ratio of -29.17 and a beta of 2.19. The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10. Mesoblast Limited has a 52-week low of $9.88 and a 52-week high of $21.50. The business has a 50-day moving average price of $15.52 and a 200 day moving average price of $16.79.
Mesoblast (NASDAQ:MESO – Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $25.67 million during the quarter. Equities research analysts forecast that Mesoblast Limited will post -0.7 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of MESO. Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesoblast in the fourth quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mesoblast by 30.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock valued at $43,000 after purchasing an additional 558 shares during the period. JPMorgan Chase & Co. grew its holdings in Mesoblast by 55.6% during the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after acquiring an additional 1,012 shares during the period. JFS Wealth Advisors LLC acquired a new position in Mesoblast during the third quarter worth $54,000. Finally, Farther Finance Advisors LLC acquired a new position in Mesoblast during the third quarter worth $58,000. Institutional investors and hedge funds own 1.43% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Mesoblast currently has an average rating of “Hold”.
Get Our Latest Stock Report on MESO
Mesoblast Company Profile
Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.
The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.